CETP and metabolic syndrome: The in vivo results of the present study showed that Tx patients with and without statin therapy had moderate dyslipidemia, dyslipoproteinemia, and atherogenic lipid and lipoprotein ratios, decreased LCAT mass, and slightly increased hsCRP, but no CETP activity.